Stock Watch: J&J’s Pharmaceuticals Division In The Shade Again
Muted Start To Fourth-Quarter Earnings Season
When facing the loss of exclusivity of your biggest product, bold deployments of capital are required to maintain sales growth, not stock buy-backs.
